Phase Ell, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum-based chemotherapy (INTEREST)

被引：5

作者：

Douillard, J. Y.

Kim, E. S.

Hirsh, V.

Mok, T.

Socinski, M.

Gervais, R.

Wu, L. Y.

Li, L.

Sellers, M.

Lowe, E.

机构：

[1] Site Hosp Nord, Ctr Rene Gauducheau, Nantes, France

[2] MD Anderson Canc Ctr, Houston, TX USA

[3] McGill Univ, Montreal, PQ, Canada

[4] Prince Wales Hosp, Hong Kong, Peoples R China

[5] Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[6] Ctr Francois Baclesse, F-14021 Caen, France

[7] Guangdong Peoples Hosp, Lung Canc Res Inst, Ctr Canc, Guangzhou, Peoples R China

[8] Beijing Union Med Coll Hosp, Ctr Canc, Lung Canc Res Inst, Beijing, Peoples R China

[9] AstraZeneca, Res & Clin Dev, Macclesfield, Cheshire, England

[10] AstraZeneca, Wilmington, DE USA

来源：

EJC SUPPLEMENTS | 2007年 / 5卷 / 06期

关键词：

D O I：

10.1016/S1359-6349(07)70095-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2LB

引用

页码：2 / 2

页数：1